diagnosis) and inspected arbitrarily chosen thresholds, which could suitably classify cases into these scenarios. In doing so they importantly demonstrated parallel variations of mRNA levels in both compartments when ABMR occurs. They then explored candidate transcripts in further samples through a targeted evaluation of blood samples by reverse transcription polymerase chain reaction (RT-PCR) to detect the best performing diagnostic combination of transcripts. Finally, they assessed the locked 8-gene marker most precisely hallmarking ABMR in a third additional cohort by RT-PCR on blood samples and tested different thresholds for diagnosis accuracy. It allowed independent validation of the combination of eight transcripts, which discriminate cases with or without ABMR with a high negative predictive value regardless of the current graft function or the timing of the evaluation. The identified transcripts are members of documented signal pathways of ABMR (natural killer cell, interactions between innate and adaptive immunity or antigen presentation).
These valuable data raise some questions mostly related to the application and interpretation of this method utilised in single individuals. Does the clinical context influence the validity of the combination of transcripts (i.e., subtypes and binding strength of donor-specific antibodies, ABO-incompatible transplantation, type of immunosuppression, synchronous inflammation such as infections or autoimmunity)? Has the assay the capacity to distinguish rejection subtypes (C4d-positivity or not, ABMR-related thrombotic microangiopathy (TMA) from other causes of TMA, isolated acute tubular injury, intimal arteritis, mixed rejection)? What is the kinetics of the mRNA levels (including baseline pre-transplant data, after intervention therapy, and their long term evolution)? What is the potential predictive value for up-to-come ABMR, or graft and patient outcomes? A thorough evaluation of this approach in various clinical scenarios, possibly pre-setting the interpretation of transcript levels, such as the presence of DSA (de novo or not) or proteinuria, will be essential too. One last stimulating consideration would be the correlation of these transcripts with early histological modifications only detectable by ultrastructural examination (endothelial cell modifications or early multilayering of glomerular or peritubular capillary basal membranes for instance).
These results could, if further validated, support the indication to perform diagnostic renal allograft biopsy with a reasonable amount of proof when clinicians suspect ABMR in its early form or patients are undergoing subclinical rejection. The early diagnosis of this deleterious process and its rapid suppression could subsequently ameliorate the allograft outcome significantly. It is not anticipated that such noninvasive procedures will be able to replace standard histology soon, as clinicians will still need valuable information on the activity of ABMR, on signs of chronicity and separate it from potential supplementary diseases but this study could be a milestone for the timely detection of ABMR.
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